A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients

Invasive fungal infections (IFIs) cause significant morbidity and mortality following lung transplantation [1]. Invasive aspergillosis complicates 3–15% of lung transplants, with a mortality rate between 52% and 55% [2]. The optimal approach for fungal prophylaxis following lung transplantation has not been universally agreed. Antifungal agents used include echinocandins (such as caspofungin), polyenes (amphotericin B) and triazoles (itraconazole, voriconazole and posaconazole). Itraconazole therapy is complicated by variable gastrointestinal absorption, toxicity and emerging resistance; voriconazole is often limited by side effects such as hepatic toxicity, photosensitivity and long-term concerns regarding increased risk of skin cancers; caspofungin therapy must be administered intravenously making long-term use impractical; and amphotericin-associated nephrotoxicity can be particularly problematic for patients who concurrently receive calcineurin inhibitors.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research